-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on BridgeBio Pharma, Raises Price Target to $110

Benzinga·08/11/2026 15:50:25
语音播报
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $95 to $110.